Article Text

Download PDFPDF

SF013/#236 Robotic approach for a total hysterectomy bilateral salpingo-oophorectomy and suction curettage of a 20-week size uterus with gestational trophoblastic neoplasia
  1. V Gupta1,
  2. S Salvador2,
  3. W Gotlieb2 and
  4. S Lau2
  1. 1McGill University, Gynaecologic Oncology, Montreal, Canada
  2. 2McGill University, Jewish General Hospital, Gynecology Oncology, Montreal, Canada


Introduction Gestational trophoblastic neoplasia (GTN) is a malignant trophoblastic disease following either molar or non-molar pregnancies. GTN is primarily treated through uterine evacuation using suction curettage followed by observation or adjuvant chemotherapy based on WHO risk scoring.1,2 In patients who have completed child-bearing, hysterectomy is an acceptable option and may decrease time to remission and required chemotherapy cycles.2 In patients presenting with large volume uterine disease, evidence of metastasis, and high-risk WHO scoring, patients are treated with multi-agent chemotherapy including Etopisode, Methotrexate, Actinomycin-D, Cycophosphamide, and Vincristine (EMA-CA).1,2 EMA-CO has significant risks of complications, including acute hemorrhage and trophoblastic emboli.2,3 In patients with large uteri, surgical risks include uterine perforation and acute hemorrhage,4 requiring a large laparotomic incision. Accordingly, there is a need for risk-reducing minimally invasive approaches in the surgical treatment of GTN.

Description The patient is a 53 year old G4P4 presenting with an enlarged uterus of 20 cm with snowstorm appearance, a beta-hCG >400 000IU, lung metastases and a WHO risk score of 8. Preoperatively her blood pressure was 168/105. She underwent a robotic total hysterectomy and bilateral salpingo-oophorectomy, and guided suction curettage. Blood loss was minimal. The patient was scored post-procedure as WHO low risk (3). She received methotrexate, and switched to Actinomycin-D after a plateau in beta-hCG. Her beta-hCG is normal 5 months later.

Conclusion We present a minimally invasive approach that ameliorates the surgical and chemotherapy risks of uterine rupture, acute hemorrhage, and trophoblastic emboli, with a normalization of beta-hCGs after treatment with single-agent chemotherapy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.